Geron Corporation (GERN) Stock: Is This Worth Your Investment?

Geron Corporation (NASDAQ: GERN) has been a hot topic among biotechnology investors for some time now, and for good reason. Recently, investors have been paying attention to the overall survival rate data that was released from the IMbark clinical trial, which is admittedly impressive. This has led to a dramatic run that the stock remains … Read more

Do Nothing Investing | KO, JNJ, WFC, AXP

“Assiduity is the ability to sit on your ass and do nothing until a great opportunities presents itself” – Charlie Munger Charlie Munger is Warren Buffett’s right-hand-man. Munger is known for his quotable investing wisdom. The above quote talks about not doing anything until a great opportunity presents itself. Once a great opportunity has presented … Read more

Healthcare Stocks Worth A Close Look | Anacor Pharmaceuticals (ANAC) | Johnson & Johnson (JNJ) | Gilead Sciences (GILD)

Today is another great day in US Markets as it seems as though the Greek and Chinese fueled correction is over. I was digging through healthcare earlier today and I was able to dig up a few opportunities that I figured I would share. Here’s what I found Anacor Pharmaceuticals Is Down, But Not For … Read more

Johnson & Johnson to Rebound? What to Expect from Tomorrow’s Report.

Johnson & Johnson (JNJ) reports its FQ2 ’15 results before the market opens tomorrow and both Estimize and Wall Street are predicting a quarter-on-quarter (QoQ) uplift in EPS and revenues. Despite the positive outlook for this quarter’s result, Johnson & Johnson’s stock year-to-date (YTD) has not performed well falling 4.42% relative to the S&P 500 … Read more

Johnson & Johnson (JNJ) Stock Climbs On Positive Earnings

Johnson & Johnson (NYSE: JNJ) Johnson & Johnson released its first fiscal quarter of 2015 earnings report today beating both EPS and top-line estimates. As a result, the company’s stock climbed in early trading before a correction followed by steady gains in the afternoon. Here’s what we saw in the earning report, what we saw … Read more